novo nordisk weight loss news - Search News

Novo Nordisk shares plummet

Retail investors buy Novo dip after disappointing weight-loss drug data

U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected obesity drug data offered a rare dip-buying opportunity, according to Vanda Research.

Hosted on MSN · 4d

Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late-stage clinical trial findings reported Friday.

New York Post on MSN · 4d

Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.

3h

Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

4d

Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up

As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results